Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00124098
Status:
COMPLETED
Last Update Posted:
2008-06-16
First Post:
2005-06-30
Brief Title:
An Evaluation of Aranesp in Subjects With Anaemic Chronic Kidney Disease CKD
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-Label Study of Aranesp Darbepoetin Alfa Administration Once Every Four Weeks in Anaemic Chronic Kidney Disease CKD Subjects
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess if Aranesp administered once every 4 weeks to chronic kidney disease subjects is safe and efficacious in maintaining haemoglobin levels greater than or equal to 100 gL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None